{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-043519","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.905139+00:00","generated_at":"2026-06-04T00:01:46.905648+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akari Therapeutics receives Nasdaq delisting notice for stockholders' equity deficit","bullets":["Stockholders' deficit of $229,000 at Dec 31, 2023 violates Nasdaq's $2.5M minimum equity requirement.","Company received delisting notice on April 5, 2024; must submit compliance plan by May 20, 2024.","If Nasdaq accepts plan, extension possible through Oct 2, 2024 to regain compliance.","Failure to regain compliance may result in delisting; company can request hearing to stay."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-043519","json":"https://secwatch.observer/filing/0000950170-24-043519.json","markdown":"https://secwatch.observer/filing/0000950170-24-043519.md","text":"https://secwatch.observer/filing/0000950170-24-043519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024043519/0000950170-24-043519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024043519/aktx-20240405.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:01:46.905648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bbd1586dfd6dbad0df1afc8ab122a4870080c101","claim":"Akari Therapeutics Plc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"April 5, 2024, Akari Therapeutics, Plc (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024043519/0000950170-24-043519-index.htm","confidence":0.98,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}